Penn Medicine Release
FOR IMMEDIATE RELEASE
June 2, 2011
(Findings will be presented at the American Society of Clinical Oncology Meeting at 3:15 pm CST on June 6, 2011)
Cell: (215) 200-2313
ASCO Abstract #1501: Is hormone replacement therapy (HRT) following risk-reduction salpingo-oophorectomy (RRSO) in BRCA1 (B1) and BRACA2 (B2) - mutation carriers associated with an increased risk of breast cancer?
Women with BRCA Mutations Can Take Hormone-Replacements Therapy Safely After Ovary Removal, Penn Researchers Report at ASCO
(CHICAGO) –– Women with the BRCA1 or BRCA2 gene mutations, which are linked to a very high risk of breast and ovarian cancer, can safely take hormone-replacement therapy (HRT) to mitigate menopausal symptoms after surgical removal of their ovaries, according to new research from the Perelman School of Medicine at the University of Pennsylvania which will be presented Monday, June 6 during the American Society for Clinical Oncology’s annual meeting. Results of the prospective study indicated that women with BRCA mutations who had their ovaries removed and took short-term HRT had a decrease in the risk of developing breast cancer... Read More